Trial Profile
A Phase II, Two-Stage, Trial of Pembrolizumab in Cancer of Unknown Primary
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Cancer
- Focus Therapeutic Use
- Acronyms CUPem
- 05 Dec 2023 Planned End Date changed from 30 Nov 2022 to 30 Sep 2024.
- 05 Dec 2023 Planned primary completion date changed from 30 May 2022 to 31 Mar 2024.
- 05 Dec 2023 Status changed from recruiting to active, no longer recruiting.